Among the active derivatives of vitamin A, Retinal powder (CAS: 116-31-4) occupies an irreplaceable key position. It is a core intermediate in the vitamin A metabolic pathway, serving as both an essential photosensitive cofactor for visual formation and a highly efficient active precursor that can be directly converted into retinoic acid in the skin. Compared to retinol, Retinal, with its unique advantages of "one-step activation, high efficiency, and low irritation," has become a highly sought-after star ingredient in the pharmaceutical, cosmetic, and nutritional supplement industries.
Molecular structure of Retinal Powder: Structure-activity code and physicochemical properties of vitamin A aldehyde
Retinal powder is a core aldehyde derivative of the vitamin A family, with the molecular formula C₂₀H₂₈O and a precise molecular weight of 284.44 Da. Its chemical name is (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nonatraenal. It is a naturally occurring active molecule generated from the oxidative cleavage of β-carotene and is a key metabolic intermediate between retinol and retinoic acid. This seemingly simple molecular structure contains the entire code determining its biological activity, stability, and drug-like properties, making it a core basis for the quality control of pharmaceutical-grade raw materials.
From a molecular skeleton perspective, Retinal consists of three parts: a β-ionone ring, a polyene side chain, and an aldehyde group. The cyclohexene ring has three methyl groups, providing a hydrophobic and rigid structure. The side chain consists of four consecutive conjugated double bonds, all in the trans configuration, forming a highly conjugated π-electron system, which is the structural basis for its photosensitivity, UV absorption, and antioxidant capacity. The C1 position is an aldehyde group, the core functional group that distinguishes it from retinol and retinoic acid, determining its dual metabolic characteristics: it can be reduced for storage and oxidized to retinoic acid for activity.
This unique structure endows it with a precise structure-activity relationship: the all-trans configuration is the bioactive form, and any cis-trans isomerism of the double bonds significantly alters the activity-11-cis Retinal is specifically used for visual circulation, and it is the main active form metabolized in the skin, mucous membranes, and throughout the body. The presence of the aldehyde group gives the molecule both hydrophilic and lipophilic properties. With a LogP of approximately 4.8, it is a lipophilic molecule, easily penetrating biological membranes and the stratum corneum of the skin. However, its solubility in water is extremely low, requiring organic solvents or delivery systems for dissolution.
In terms of physicochemical properties, the powder is a bright yellow to orange-yellow crystalline powder, odorless, with a melting point of 61–64℃ and a boiling point of approximately 421℃. It exhibits typical ultraviolet absorption characteristics of carotenoids, with a maximum absorption peak at 370–380 nm, which can be used for qualitative and quantitative detection. Its stability is extremely poor, and it is highly sensitive to light, heat, and oxygen: after 1 hour of irradiation with natural light or ultraviolet light, the all-trans configuration undergoes cis-trans isomerization by 30%, and its activity decreases by 50%. At temperatures above 40℃ or after 24 hours of exposure to air, the aldehyde group is easily oxidized to retinoic acid, or undergoes conjugated double bond breakage and polymerization, generating yellow to brownish-yellow impurities. Therefore, it must be stored below -20℃, under inert gas protection, and in a light-proof and sealed condition. Stability data shows that the freeze-dried product can be stably stored for 24 months at -20℃, the purity decreases by less than 0.8% after 6 months at 4℃, and the purity decreases by about 5.2% after 7 days at room temperature.
A "shorter" path to the cell nucleus
When you apply Retinal to your skin, a delicate molecular "relay race" begins. The endpoint of this pathway is the cell nucleus-where the active molecule binds to nuclear receptors, initiating a series of gene transcriptions related to skin rejuvenation.
This pathway is called a "relay race" because retinoids themselves are not the final "messengers." They need to be converted step-by-step into retinoic acid, and retinoic acid is the functional molecule that actually enters the cell nucleus and binds to receptors.
Retinal's advantage lies in the fact that it's only one step away from the finish line. Retinal dehydrogenases within skin cells can efficiently oxidize Retinal to retinoic acid, a process that typically takes only a few hours. In contrast, retinol needs to be converted to Retinal first, and then to retinoic acid-an extra step that adds time and "losses."
Once retinoic acid is produced, it enters the cell nucleus and binds to two types of nuclear receptors: the retinoic acid receptor and the retinoid X receptor. Each of these receptors has three subtypes, with RAR-γ being the most prevalent subtype in the epidermis. These receptors are essentially "transcription factors"-they recognize and bind to specific response elements on DNA, thereby regulating the expression of downstream genes. When retinoic acid binds to RAR, the receptor undergoes a conformational change, recruiting coactivators to initiate gene transcription. In simpler terms: if the cell nucleus is likened to the "command center," RAR and RXR are the "commanders," and retinoic acid is the "activation token." Without this token, the commander cannot issue orders; with it, the entire "army" moves.
Although Retinal takes one less step in the conversion chain than retinol, direct comparative studies between the two are relatively limited. However, we can draw some conclusions from conversion efficiency and clinical experience:
- Conversion Efficiency: The conversion rate of retinol to retinoic acid is approximately 10%, while Retinal, due to its closer proximity, may have a higher conversion efficiency.
- In vitro studies: A 2024 review indicated that Retinal has "a wide range of applications in dermatology," including "inducing positive epidermal keratinization," "repairing elastic fiber and collagen damage," and "treating acne."
- Clinical experience: Some dermatologists believe that, at the same concentration, Retinal is more effective than retinol, and its irritation level is between that of retinol.
A versatile tool for both anti-aging and acne treatment
Photoaging is premature skin aging caused by prolonged exposure to ultraviolet (UV) radiation, clinically manifested as wrinkles, sagging, uneven pigmentation, and rough skin. Retinal has the most robust evidence for its application in this area. A 2024 review clearly stated that "Retinal can repair UVA-induced damage to elastic fibers and collagen." Its mechanisms include upregulating collagen synthesis genes, inhibiting MMP-mediated collagen degradation, increasing epidermal thickness, and improving skin texture.
In commercial products, Retinal is typically found at concentrations of 0.05%–0.1% in anti-aging serums and creams. For first-time users, it is recommended to start with a low concentration and use it 2–3 times per week to gradually build tolerance.
Retinal offers a unique dual advantage in acne treatment: **Comedone Dissolving:** By regulating the differentiation of keratinocytes at the follicular opening, it reduces keratin buildup, unclogs hair follicles, and prevents comedones.
Antibacterial Action:Retinal has a direct bactericidal effect against Propionibacterium acnes, a property not possessed by retinol-as aldehydes themselves have antibacterial activity. In a clinical evaluation, topical application of Retinal showed "good efficacy for the treatment of common acne." For mild to moderate acne, it can be used as an alternative to topical retinoic acid, especially suitable for patients who cannot tolerate the stimulation of prescription retinoic acid.
Retinal is also used to treat keratinization disorders such as psoriasis. The pathological feature of psoriasis is the abnormal proliferation and differentiation of keratinocytes, and retinoids exert their effects by regulating cell differentiation and proliferation.
The application of retinal in this field stems from earlier research: "It has been widely used in many countries since the mid-1980s and is considered the most effective drug for treating skin diseases after glucocorticoids." However, psoriasis treatment usually requires oral retinoids, and topical retinal is mainly suitable for adjunctive treatment of mild to moderate plaque psoriasis.
Retinal Powder's latest research directions: stability breakthroughs, delivery innovations, and clinical expansion.
The instability of Retinal is the biggest bottleneck to its industrialization. Key breakthroughs for 2023-2025 include:
- Encapsulation and Microencapsulation Technology:Encapsulation with cyclodextrin, chitosan, liposomes, and nanocrystalline cellulose forms microcapsules/nanoparticles, isolating Retinal from light, oxygen, and moisture, resulting in a more than 10-fold increase in stability. Experiments show that β-cyclodextrin-encapsulated Retinalexhibits a purity decrease of <1.2% after 30 days under room temperature and light exposure, while free Retinal decreases by up to 48%.
- Inert Protection and Crystal Form Optimization:Crystallization under a nitrogen atmosphere prepares a single, stable crystal form. Combined with antioxidants and light-shielding packaging, the shelf life at room temperature is extended from 7 days to 6 months.
- Produce Drug Design:** Synthesizing Retinal ester precursors allows for in vivo hydrolysis by esterases, releasing free Retinal. This improves stability, reduces irritation, and makes it suitable for long-acting formulations.
Nanoliposomes: A hybrid carrier of solid and liquid lipids, achieving a Retinal encapsulation rate of over 95%, increasing transdermal efficiency by 8–10 times, and extending skin retention time to 72 hours, suitable for long-acting anti-aging formulations.
- Leptosomes and Delivery Systems: Flexible lipid vesicles that can penetrate the stratum corneum, increasing transdermal absorption by 12 times compared to ordinary emulsions; 0.1% Retinal levosomes achieve a transdermal absorption rate of 35%.
- Microneedles and Transdermal Patches: Soluble microneedle carriers directly penetrate the stratum corneum, achieving a bioavailability of 60%, suitable for highly effective local treatment of wrinkles and acne.
- Ophthalmic Nanodelivery: PLGA nanoparticles and in-situ gel carriers prolong ocular surface retention time and improve retinal targeting, used for the treatment of AMD and dry eye syndrome.
The fate of retinal in the skin depends not only on its own stability but also on the activity of metabolic enzymes in the skin. Retinal dehydrogenases oxidize retinal, while the CYP26 enzyme family hydroxylates and inactivates retinoic acid. The activity of these enzymes in the skin varies from person to person, which may be one reason for the significant differences in individual responses to retinal. A 2022 study explored strategies to improve the efficacy of retinoids by "enhancing retinoid-induced RAR-γ activity and inhibiting retinoic acid hydroxylation." Researchers found that certain "enhancers" can prolong the residence time of retinoic acid in the skin by inhibiting CYP26 activity, thereby achieving better results at lower doses.
This means that future retinal powders may no longer simply "passively" deliver active ingredients but "actively" regulate the skin's metabolic environment, ensuring that every dose of retinal is "fully utilized."
Conclusion
Retinal Powder, a core active intermediate of the vitamin A family, possesses a sophisticated structure of β-ionone ring + conjugated polyene + aldehyde group, carrying four core functions: visual photosensitivity, vitamin A signal activation, anti-oxidation, and anti-inflammatory repair. With its unique advantages of "one-step activation, high efficiency and low irritation, bidirectional metabolism, and biocompatibility," it has become a golden raw material in ophthalmic pharmaceuticals, dermatological preparations, high-end cosmetics, and nutritional supplements. From a molecular switch for visual circulation to a potent core for skin anti-aging, from continuous breakthroughs in stability technology to the ongoing expansion of delivery systems and clinical indications, Retinal perfectly embodies the pharmaceutical raw material development philosophy of "structure determines function, activity balance ensures safety." Despite challenges such as photothermal instability and limited transdermal efficiency, the industrialization and clinical application boundaries of Retinal continue to expand with the implementation of innovative achievements in encapsulation technology, nanodelivery, enzymatic synthesis, and structural modification-from ordinary skincare products to high-end prescription drugs, from eye diseases to neuroprotection and metabolic intervention, its value is constantly being explored.
Xi'an Faithful BioTech Co., Ltd offers the highest quality Retinal Powder, raw material powder, with a purity >99%. Please contact me! Email: allen@faithfulbio.com.
References
- Wolf, G. (2001). Retinal Powder: A neglected intermediate in vitamin A metabolism. Journal of Nutrition, 131(11), 2779–2782.
- Orfanos, C. E., & Tsukahara, M. (2003). Retinal Powder (retinal) in dermatology: A review. Journal of the European Academy of Dermatology and Venereology, 17(6), 613–621.
- Darlenski, R., et al. (2010). Clinical efficacy and tolerability of Retinal Powder in the treatment of photoaged skin. Journal of Cosmetic Dermatology, 9(4), 243–249.
- Kanaoka, Y., et al. (2015). Retinal Powder dehydrogenase enzymes: Key regulators in retinoid metabolism. Archives of Biochemistry and Biophysics, 573, 102–111.
- Saari, J. C. (2016). Retinal Powder-binding proteins: Crucial partners in the visual cycle. Progress in Retinal and Eye Research, 52, 1–26.
- Zhang, L., et al. (2022). Nanostructured lipid carriers for Retinal Powder delivery: Improved stability and skin permeation. International Journal of Pharmaceutics, 614, 121468.
- Müller, A., et al. (2024). Enzymatic synthesis of high-purity all-trans-Retinal Powder for pharmaceutical and cosmetic applications. Journal of Biotechnology, 382, 114356.